Linsitinib Shows Promise in Reducing Proptosis in Thyroid Eye Disease
• Linsitinib, an oral small molecule, significantly reduced proptosis in patients with active, moderate to severe thyroid eye disease (TED) in a Phase 2b/3 trial.
• The LIDS trial met its primary endpoint, demonstrating a statistically significant proptosis responder rate of 52% (p = 0.01) at Week 24 with the 150mg BID dose.
• Linsitinib exhibited a favorable safety profile, with no drug-related hearing impairment, tinnitus, or menstrual cycle changes reported in the trial.
• Sling Therapeutics plans to initiate a confirmatory Phase 3 trial in 2025, aiming to provide a convenient oral treatment option for TED patients.
Viridian's Veligrotug Shows Promise in Phase 3 Trial for Chronic Thyroid Eye Disease
• Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the THRIVE-2 Phase 3 trial for chronic thyroid eye disease (TED).
• The trial demonstrated statistically significant improvements in proptosis, diplopia, and clinical activity scores (CAS) after five infusions of veligrotug.
• A Biologics License Application (BLA) submission for veligrotug is on track for the second half of 2025, potentially transforming TED treatment.
• Viridian is advancing VRDN-003, a subcutaneous anti-IGF-1R antibody, with topline data expected in the first half of 2026.
Sarilumab Facilitates Steroid Tapering More Effectively Than Methotrexate in Polymyalgia Rheumatica
• A recent study presented at ACR Convergence 2024 indicates sarilumab is more effective than methotrexate in helping polymyalgia rheumatica (PMR) patients discontinue steroid use.
• The study found that 59% of PMR patients on sarilumab could discontinue glucocorticoids within 6 months, compared to 35% on methotrexate.
• Sarilumab-treated patients also required fewer days on steroids and a lower cumulative steroid dose compared to those treated with methotrexate.
• These findings suggest sarilumab can minimize steroid-related toxicities in older PMR patients, offering an evidence-based treatment option.
© Copyright 2025. All Rights Reserved by MedPath